The availability of biotechnological drugs, increasingly targeted to pivotal mediators of pathogenesis of psoriasis, has significantly improved the therapeutic perspectives as well as the quality of life of patients with psoriasis. The use of this class of molecules for more than a decade allows them to be considered safe, even in long‐term, continuous treatment. A multicenter, phase III randomized trial showed that the increase in dosing frequency significantly improves ixekizumab efficacy without affecting the safety profile of the treatment provides evidence for strengthening its therapeutic potential.
Evidence for improving the therapeutic response to ixekizumab: more than just a statistic
Borghi A.
2018
Abstract
The availability of biotechnological drugs, increasingly targeted to pivotal mediators of pathogenesis of psoriasis, has significantly improved the therapeutic perspectives as well as the quality of life of patients with psoriasis. The use of this class of molecules for more than a decade allows them to be considered safe, even in long‐term, continuous treatment. A multicenter, phase III randomized trial showed that the increase in dosing frequency significantly improves ixekizumab efficacy without affecting the safety profile of the treatment provides evidence for strengthening its therapeutic potential.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Ixekizumab-2018-British_Journal_of_Dermatology.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
67.49 kB
Formato
Adobe PDF
|
67.49 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.